Investor Relations

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

Recent Releases

Date Title and Summary
Toggle Summary Celldex Announces Initiation of CDX-0159 Subcutaneous Formulation Study
HAMPTON, N.J. , Sept. 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first cohort has been dosed in the Phase 1 study of the subcutaneous formulation of CDX-0159 in healthy volunteers. CDX-0159 is a humanized monoclonal antibody that specifically
Toggle Summary Celldex Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- Positive data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria presented at EAACI 2021 - - Raised $287 million in gross proceeds from a follow-on public offering of common stock, closed in July 2021 - HAMPTON, N.J. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc.

Upcoming Events

There are currently no events to display.

Featured Financial Reports

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

 

Our Pipeline